News & Updates

Myocarditis, pericarditis not uncommon with mRNA-1273 COVID-19 vaccines
Myocarditis, pericarditis not uncommon with mRNA-1273 COVID-19 vaccines
26 Nov 2022

Although the incidence of myocarditis or pericarditis following mRNA COVID-19 vaccination is low, a two- to threefold higher likelihood is seen among individuals who received mRNA-1273 compared to BNT162b2 vaccine, reveals a study.

Myocarditis, pericarditis not uncommon with mRNA-1273 COVID-19 vaccines
26 Nov 2022
Which factors raise HCC risk in patients with cured HCV?
Which factors raise HCC risk in patients with cured HCV?
24 Nov 2022 byStephen Padilla

Predictors of hepatocellular carcinoma (HCC) differ in patients with virologically cured hepatitis C virus (HCV) infection with and without cirrhosis, according to a study. However, changes in fibrosis-4 (FIB-4) scores over time are associated with HCC risk in both cohorts.

Which factors raise HCC risk in patients with cured HCV?
24 Nov 2022
ANCA-positive infective endocarditis tied to longer disease duration, kidney injury
ANCA-positive infective endocarditis tied to longer disease duration, kidney injury
22 Nov 2022

A significant number of patients with infective endocarditis have been found to have antineutrophil cytoplasmic antibody (ANCA), which is associated with longer disease duration, more frequent purpura, and kidney involvement, results of a study has shown.

ANCA-positive infective endocarditis tied to longer disease duration, kidney injury
22 Nov 2022
Entecavir plus traditional Chinese medicine cuts HCC risk in CHB
Entecavir plus traditional Chinese medicine cuts HCC risk in CHB
22 Nov 2022

Among patients with chronic hepatitis B (CHB), treatment with entecavir (ETV) and Biejia-Ruangan compound (BRC), an antifibrotic traditional Chinese medicine, helps reduce the risk of hepatocellular carcinoma (HCC), a recent study reports.

Entecavir plus traditional Chinese medicine cuts HCC risk in CHB
22 Nov 2022
TB rates elevated after ART initiation in PLHIV
TB rates elevated after ART initiation in PLHIV
21 Nov 2022 byRoshini Claire Anthony

People living with HIV (PLHIV) who initiate antiretroviral therapy (ART) are at an increased risk of developing tuberculosis (TB), particularly in the first 3 months after starting ART, according to a study presented at HIV Glasgow 2022.

TB rates elevated after ART initiation in PLHIV
21 Nov 2022
COVID-19 may trigger hair, nail disorders
COVID-19 may trigger hair, nail disorders
21 Nov 2022

Hair and nail disorders may occur following contraction of COVID-19 infection, with the development of the dermatological conditions related to a history of severe infection, a study has found.

COVID-19 may trigger hair, nail disorders
21 Nov 2022
H. pylori eradication eases metabolic dysfunction, steatosis in NAFLD
H. pylori eradication eases metabolic dysfunction, steatosis in NAFLD
20 Nov 2022

Among patients with nonalcoholic fatty liver disease (NAFLD), eradication treatment against Helicobacter pylori may help improve liver steatosis and metabolic parameters, a recent study has found.

H. pylori eradication eases metabolic dysfunction, steatosis in NAFLD
20 Nov 2022